Related Experiment Video
Updated: May 15, 2026
09:26
Generation of Lymphocytic Microparticles and Detection of their Proapoptotic Effect on Airway Epithelial Cells
Published on: February 20, 2015
Increased endothelial microparticles in obese and overweight children
Zübeyde Gündüz1, İsmail Dursun, Sebahat Tülpar
1Faculty of Medicine, Department of Pediatric Nephrology, Erciyes University, 38039 Kayseri, Turkey.
Journal of Pediatric Endocrinology & Metabolism : JPEM
|January 19, 2013
Summary
Childhood obesity is linked to early endothelial damage. Obese children show higher levels of circulating endothelial microparticles (EMPs), indicating dysfunction may be related to weight.
Area of Science:
- Pediatric Cardiology
- Vascular Biology
- Metabolic Disorders
Background:
- Childhood obesity is a growing concern, increasing the risk of atherosclerosis.
- Endothelial dysfunction is a key factor in atherosclerosis development.
- Endothelial microparticles (EMPs) serve as potential biomarkers for endothelial dysfunction.
Purpose of the Study:
- To evaluate circulating EMPs in obese and overweight children.
- To identify the obesity measure most strongly associated with EMPs and carotid atherosclerosis.
Main Methods:
- Prospective study of 55 obese/overweight children and 23 controls.
- Measured circulating EMPs (CD144+, CD146+) via flow cytometry.
- Assessed carotid intima-media thickness (cIMT) and left ventricular mass index (LVMI) via ultrasound/echocardiography.
Main Results:
- Higher blood pressure, CD144+EMP levels, and LVMI in the patient group.
- CD144+EMP and systolic blood pressure showed a linear relationship with overweight and obesity.
Conclusions:
- Endothelial damage begins in early childhood obesity.
- Increased circulating CD144+EMPs in obese children suggest a link between endothelial dysfunction and obesity.
Related Concept Videos
01:25Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
01:20Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
01:24Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
01:21Drug Dosing: Obese Patients
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...